With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
The peptide-based vaccine induces a t cell-dependent response
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
According to the Indian Council of Medical Research (ICMR), there will be an estimated 12 % rise in cancer cases in India in the next five years
Tislelizumab is now approved for seven indications in China
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
